REG - Proteome Sciences - Substantial Contract Win

Proteome SciencesAnnouncement

20/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211220:nRST1202Wa&default-theme=true

RNS Number : 1202W  Proteome Sciences PLC  20 December 2021

 

 

 

Prior to publication, the information contained within this announcement was
deemed by the Company to constitute inside information as stipulated under the
UK Market Abuse Regulations. With the publication of this announcement, this
information is now considered to be in the public domain.

20 December 2021

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Substantial contract win for Proteome Sciences

London, December 20, 2021.  Proteome Sciences is pleased to announce that the
Company has secured a contract in excess of GBP 1 million from a major
pharmaceutical company to analyse large cohorts of clinical samples from a
phase 3 clinical trial. Work is expected to start early in the first quarter
of 2022 and the majority of revenue is expected to be generated in 2022.

Commenting on the contract, Richard Dennis, Chief Commercial Officer of
Proteome Sciences said:

"We are delighted that Proteome Sciences has been selected as the biomarker
CRO of choice for these ongoing clinical studies. The contract will take up a
significant part of the expanded capacity that we have added to our services
activities in 2022 and into 2023. Our proprietary proteomics services using
Tandem Mass Tags (TMTpro) was key to selecting Proteome Sciences as was the
intellectual property in our TMTcalibrator technique to boost the sensitivity
of mass spectrometry in their selected sample types."

- Ends -

For further information:

 Proteome Sciences plc

 Richard Dennis, Chief Commercial Officer       Tel: +44 (0)20 7043 2116

 Dr Mariola Soehngen, Chief Executive Officer

 Dr Ian Pike,  Chief Scientific Officer

 Allenby Capital Limited (AIM Nominated Adviser & Broker)
 John Depasquale/ Jeremy
 Porter                           Tel: +44 (0)20 3328
 5656

About Proteome Sciences plc. (www.proteomics.com (http://www.proteomics.com) )

 

Proteome Sciences plc is a specialist provider of contract proteomics services
to enable drug discovery, development and biomarker identification, and
employs proprietary workflows for the optimum analysis of tissues, cells and
body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and
contextualising new targets and defining mechanisms of biological activity,
while analysis using Super-Depletion and TMTcalibrator™ provides access to
over 8,500 circulating plasma proteins for the discovery of disease-related
biomarkers. Targeted assay development using mass spectrometry delivers high
sensitivity, interference-free biomarker analyses in situations where standard
ELISA assays are not available.

 

The Company has its headquarters in London, UK, with laboratory facilities in
Frankfurt, Germany.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUKUARAVUUAUA